- Published: November 30, 2018
- Written by Jill O-Donnell-Tormey, PhD
Jill O'Donnell-Tormey, PhD, is chief executive officer and director of scientific affairs at the Cancer Research Institute. In 2017, CRI and the Focused Ultrasound Foundation partnered with the goal of advancing the development of new focused ultrasound and cancer immunotherapy treatments. A major part of the partnership is a joint fund that supports research to move toward new combination therapies. That fund awarded its first research grant in June of 2018. Dr. O’Donnell-Tormey appeared at the 6th International Symposium on Focused Ultrasound in October to discuss the partnership. Below is an edited transcript of our interview with her.
Why did you partner with Focused Ultrasound Foundation?
As immunotherapy was starting to gather momentum and there were more FDA approvals of immunotherapy, the Focused Ultrasound Foundation thought there might be a place to combine immunotherapy and focused ultrasound. So that was the impetus.